Starpharma Registered its COVID-19 antiviral nasal spray in Europe

  • February 23, 2021 01:41 PM AEDT
  • Team Kalkine

ASX 300-listed global biopharmaceutical company Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) has registered its COVID-19 antiviral nasal spray VIRALEZE™,  for sale in Europe, including the UK.

Gold MTF non-AMP

Here are some key highlights-

  • Starpharma is delighted to have completed the registration of VIRALEZE™ in Europe and the UK ahead of the original schedule.
  • With this registration, Starpharma will market VIRALEZE™ across the European Economic Area (EEA).
  • Starpharma disclosed that the European launch of VIRALEZE™ is on track, and the nasal spray is anticipated to be available for online sale starting from next month.
  • The Company stated that preparations for launch are well advanced with the manufacturing of the batches in progress.
  • SPL is planning to launch VIRALEZE™ in other countries, including Australia, and its European registration and the regulatory dossier will be used as the basis to obtain further marketing approvals.

On 23 February 2021, SPL shares were trading at A$2.25, up by 2.272% at AEDT 1:19 PM.

DETAILED DISCUSSION AT: Why are Starpharma (ASX:SPL) shares moving north today?


The website is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK